Application of dopamine receptor 1 antagonist in preparing drugs for treatment of ketamine-induced schizoid symptoms in mice

Abstract

The invention belongs to the technical field of biomedicine and particularly relates to a novel pharmaceutical use of a dopamine receptor 1 antagonist, and to a novel use of the dopamine receptor 1 antagonist in preparing drugs for the treatment of ketamine-induced schizoid symptoms in mice. The dopamine receptor 1 antagonist is selected from SCH23390 having a molecular formula of C17H18ClNO.HCl,and is one or only one effective ingredient to the drugs. A drug for the treatment of ketamine-induced schizoid symptoms in mice comprises the dopamine receptor 1 antagonist having the effective amount (5 mg/kg). The dopamine receptor 1 antagonist is used as one means to treat ketamine-induced schizoid behaviors of mice, and scientific basis is provided for the research and development of a methodto effectively relieve schizoid symptoms in mice.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and in particular relates to a new medicinal use of a dopamine receptor 1 antagonist, in particular to a new use of a dopamine receptor 1 antagonist in preparing a medicine for treating schizophrenia in mice induced by ketamine. Background technique [0002] Schizophrenia is the most serious, the most harmful, and the highest disability rate among mental diseases. Its clinical manifestations include thinking disorders (loose thinking, lack of thinking, delusions, etc.), hallucinations, affective disorders (apathy, emotional perversion), behavioral disorders (social withdrawal, strange behavior, nervous excitement, etc.) and loss of learning and working memory. . With the deterioration of social environment and the increase of life pressure, the incidence of schizophrenia is increasing year by year. [0003] Modern medicine believes that schizophrenia is a collection of symptoms and signs of...

AI Technical Summary

Problems solved by technology

The etiology of schizophrenia is unknown, and there are few studies on its pathogenesis at present. The clinical diagnosis mainly depends on the judgment of positive symptoms and negative symptoms, and there is a lack of objective biological detection indicators. Its treatment has always been a difficult problem in the medical field. So far, no dopamine receptor 1 antagonist has been found as a target for treating or alleviating the onset of schizophrenia. Therefore, the development of a drug for the treatment of ketamine-induced schizophrenia in mice is a new topic to be solved urgently.

Images